Diagnosis of anaplastic large-cell lymphoma in a dog using CD30 immunohistochemistry
Rachel Pittaway, Ying Wu, Balázs Szladovits, Alejandro Suárez‐Bonnet, Emma Scurrell, Oliver A. Garden, Gerry Polton, Simon L. Priestnall
Abstract
Open-access reader
Rachel Pittaway, Ying Wu, Balázs Szladovits, Alejandro Suárez‐Bonnet, Emma Scurrell, Oliver A. Garden, Gerry Polton, Simon L. Priestnall
Abstract
Open-access reader
Anaplastic large-cell lymphoma or null-cell lymphoma is a clinical entity reported in people, classified according to the unique appearance of large pleomorphic cells that express CD30. Null-cell lymphoma has also been described in dogs when neither CD3 nor CD79α is expressed by the tumor. We describe a case of lymphoma in the dog in which neoplastic cells did not express routine B- or T-lymphocyte markers on flow cytometry or immunohistochemistry; however, cells immunohistochemically labeled for CD30. The dog in our case died 5 mo after initial presentation, confirming a poor prognosis. Identification of further similar cases in dogs would provide additional prognostic information for this subset of lymphomas. CD30 may also serve as a potential therapeutic target in anaplastic large-cell lymphomas.
OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Anaplastic large-cell lymphoma or null-cell lymphoma is a clinical entity reported in people, classified according to the unique appearance of large pleomorphic cells that express CD30. Null-cell lymphoma has also been described in dogs when neither CD3 nor CD79α is expressed by the tumor. We describe a case of lymphoma in the dog in which neoplastic cells did not express routine B- or T-lymphocyte markers on flow cytometry or immunohistochemistry; however, cells immunohistochemically labeled for CD30. The dog in our case died 5 mo after initial presentation, confirming a poor prognosis. Identification of further similar cases in dogs would provide additional prognostic information for this subset of lymphomas. CD30 may also serve as a potential therapeutic target in anaplastic large-cell lymphomas.
Key concepts: CD30, Anaplastic large-cell lymphoma, Lymphoma, Immunohistochemistry, Null cell, Pathology, T-cell lymphoma, Large-cell lymphoma